1
|
Bassi LS, Moreno FA, Martins CCS, Sens RF, Lozano-Poveda CA, Maiorka A. Effect of 25-hydroxycholecalciferol supplementation with different dietary available phosphorus levels for broilers. Br Poult Sci 2024; 65:71-78. [PMID: 37921562 DOI: 10.1080/00071668.2023.2278474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Accepted: 10/12/2023] [Indexed: 11/04/2023]
Abstract
1. Based on the hypothesis that 25-hydroxycholecalciferol (25-OH-D3) inclusion would optimise dietary mineral digestibility and ameliorate growth performance and bone mineralisation in available phosphorus (AvP) deficient-fed broilers, a trial was conducted to evaluate its effect on diets with different levels of AvP.2. Broilers aged 1-21 d were randomly assigned one of the eight treatments, consisting of four dietary levels of AvP (0.45%, 0.42%, 0.39%, and 0.36%) and with or without supplementation with 25-OH-D3 at 69 μg/kg of feed. All diets contained 100 µg/kg of vitamin D3 (cholecalciferol).3. The addition of 25-OH-D3 resulted in higher feed intake and body weight gain, and lower FCR (P < 0.05) compared to non-supplemented diets, whereas AvP levels had a quadratic effect only on feed intake. There were no interactions between treatment factors.4. Increasing AvP levels linearly reduced the ileal digestibility of Ca and P (P < 0.01) and supplementing 25-OH-D3 increased both Ca and P ileal digestibility (P < 0.05), without any interactions observed for ileal digestibility.5. There was an interaction, whereby 25-OH-D3 inclusion increased serum metabolites in broilers fed 0.36% to 0.42% AvP compared to the non-supplemented diets (P < 0.001), whereas, at 0.45% AvP, diets with or without 25-OH-D3 had similar results.6. The P content in bone linearly increased in line with AvP levels (P < 0.05) and supplementation of 25-OH-D3 increased ash bone content (P < 0.001).7. Broilers can benefit from 25-OH-D3 supplementation combined with cholecalciferol with regard to Ca and P utilisation and vitamin D status, allowing for a reduction of dietary AvP levels down to 0.36% without impairing growth performance or bone status.
Collapse
Affiliation(s)
- L S Bassi
- Department of Animal Science, Federal University of Paraná, Curitiba, Brazil
| | - F A Moreno
- Department of Animal Science, Federal University of Paraná, Curitiba, Brazil
| | | | - R F Sens
- DSM Nutritional Products, São Paulo, Brazil
| | | | - A Maiorka
- Department of Animal Science, Federal University of Paraná, Curitiba, Brazil
| |
Collapse
|
2
|
Ramirez AH, Sulieman L, Schlueter DJ, Halvorson A, Qian J, Ratsimbazafy F, Loperena R, Mayo K, Basford M, Deflaux N, Muthuraman KN, Natarajan K, Kho A, Xu H, Wilkins C, Anton-Culver H, Boerwinkle E, Cicek M, Clark CR, Cohn E, Ohno-Machado L, Schully SD, Ahmedani BK, Argos M, Cronin RM, O’Donnell C, Fouad M, Goldstein DB, Greenland P, Hebbring SJ, Karlson EW, Khatri P, Korf B, Smoller JW, Sodeke S, Wilbanks J, Hentges J, Mockrin S, Lunt C, Devaney SA, Gebo K, Denny JC, Carroll RJ, Glazer D, Harris PA, Hripcsak G, Philippakis A, Roden DM, Ahmedani B, Cole Johnson CD, Ahsan H, Antoine-LaVigne D, Singleton G, Anton-Culver H, Topol E, Baca-Motes K, Steinhubl S, Wade J, Begale M, Jain P, Sutherland S, Lewis B, Korf B, Behringer M, Gharavi AG, Goldstein DB, Hripcsak G, Bier L, Boerwinkle E, Brilliant MH, Murali N, Hebbring SJ, Farrar-Edwards D, Burnside E, Drezner MK, Taylor A, Channamsetty V, Montalvo W, Sharma Y, Chinea C, Jenks N, Cicek M, Thibodeau S, Holmes BW, Schlueter E, Collier E, Winkler J, Corcoran J, D’Addezio N, Daviglus M, Winn R, Wilkins C, Roden D, Denny J, Doheny K, Nickerson D, Eichler E, Jarvik G, Funk G, Philippakis A, Rehm H, Lennon N, Kathiresan S, Gabriel S, Gibbs R, Gil Rico EM, Glazer D, Grand J, Greenland P, Harris P, Shenkman E, Hogan WR, Igho-Pemu P, Pollan C, Jorge M, Okun S, Karlson EW, Smoller J, Murphy SN, Ross ME, Kaushal R, Winford E, Wallace F, Khatri P, Kheterpal V, Ojo A, Moreno FA, Kron I, Peterson R, Menon U, Lattimore PW, Leviner N, Obedin-Maliver J, Lunn M, Malik-Gagnon L, Mangravite L, Marallo A, Marroquin O, Visweswaran S, Reis S, Marshall G, McGovern P, Mignucci D, Moore J, Munoz F, Talavera G, O'Connor GT, O'Donnell C, Ohno-Machado L, Orr G, Randal F, Theodorou AA, Reiman E, Roxas-Murray M, Stark L, Tepp R, Zhou A, Topper S, Trousdale R, Tsao P, Weidman L, Weiss ST, Wellis D, Whittle J, Wilson A, Zuchner S, Zwick ME. The All of Us Research Program: Data quality, utility, and diversity. Patterns 2022; 3:100570. [PMID: 36033590 PMCID: PMC9403360 DOI: 10.1016/j.patter.2022.100570] [Citation(s) in RCA: 50] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Revised: 03/30/2022] [Accepted: 07/14/2022] [Indexed: 11/05/2022]
Abstract
The All of Us Research Program seeks to engage at least one million diverse participants to advance precision medicine and improve human health. We describe here the cloud-based Researcher Workbench that uses a data passport model to democratize access to analytical tools and participant information including survey, physical measurement, and electronic health record (EHR) data. We also present validation study findings for several common complex diseases to demonstrate use of this novel platform in 315,000 participants, 78% of whom are from groups historically underrepresented in biomedical research, including 49% self-reporting non-White races. Replication findings include medication usage pattern differences by race in depression and type 2 diabetes, validation of known cancer associations with smoking, and calculation of cardiovascular risk scores by reported race effects. The cloud-based Researcher Workbench represents an important advance in enabling secure access for a broad range of researchers to this large resource and analytical tools. The All of Us Research Program has released data for over 315,000 participants Demonstration projects support the utility and validity of the All of Us dataset The cloud-based Researcher Workbench provides secure, low-cost compute power
The engagement of participants in the research process and broad availability of data to diverse researchers are essential elements in building precision medicine equitably available for all. The NIH has established the ambitious All of Us Research Program to build one of the most diverse health databases in history with tools to support research to improve human health. Here, we present the initial launch of the Researcher Workbench with data types including surveys, physical measurements, and electronic health record data with validation studies to support researcher use of this novel platform. Broad access for researchers to data like these is a critical step in returning value to participants seeking to support the advancement of precision medicine and improved health for all.
Collapse
|
3
|
Ehrmann K, Allen JJB, Moreno FA. Psilocybin for the Treatment of Obsessive-Compulsive Disorders. Curr Top Behav Neurosci 2021; 56:247-259. [PMID: 34784024 DOI: 10.1007/7854_2021_279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Obsessive-compulsive disorder (OCD) is a highly prevalent and disabling condition for which currently available treatments are insufficiently effective and alternatives merit priority attention. Psilocybin may represent a safe and effective avenue for treatment of individuals affected by this condition. In this chapter we briefly introduce OCD symptoms, epidemiology, as well as relevant hypotheses on the mechanism of disease that may inform treatment interventions. We briefly describe currently available treatments, mechanisms of action, and efficacy limitations, as preamble to the potential use of psilocybin and perhaps similar compounds in the treatment of OCD and related conditions. Although much is reviewed throughout this book about the mechanisms of action of psychedelic agents, a focused discussion of psilocybin effects as they pertain to OCD is also included. Our experience with incidental observation, prospective research, and current explorations of psilocybin in OCD are also described.
Collapse
|
4
|
Mendoza NS, Moreno FA, Hishaw GA, Gaw AC, Fortuna LR, Skubel A, Porche MV, Roessel MH, Shore J, Gallegos A. Affirmative Care Across Cultures: Broadening Application. Focus (Am Psychiatr Publ) 2020; 18:31-39. [PMID: 32047395 DOI: 10.1176/appi.focus.20190030] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Affirmative practice is an approach to health and behavioral health care that validates and supports the identities stated or expressed by those served. Affirmative care requires the practitioner to actively honor and celebrate identity while at the same time validating the oppression felt by individuals seeking services. Validation and empathy fundamentally result from increased understanding of individuals' history, cultural context, and lived experiences. Origins of the approach honored the experience of those in LGBTQ+ communities; however, affirmative care should be valued across cultures, systems, and settings in which health and behavioral health care are offered. Affirmative care principles should be applied across cultures and communities while recognizing the worth of the individual and avoiding stereotyping. Along with delineating historical and demographic contexts, the authors offer recommendations for affirmative care in practice with African American, Asian, Indigenous, and Latinx individuals, as well as those living in rural communities.
Collapse
Affiliation(s)
- Natasha S Mendoza
- Center for Applied Behavioral Health Policy, Watts College of Public Service and Community Solutions, Arizona State University, Phoenix (Mendoza, Gallegos); College of Medicine, University of Arizona Health Sciences, Tucson and Phoenix (Moreno); College of Medicine, University of Arizona Health Sciences Center, Tucson (Hishaw); University of California, San Francisco, Medical School, San Francisco (Gaw); Boston Medical Center, School of Medicine (Fortuna), and Wheelock College of Education and Human Development (Skubel, Porche), all at Boston University, Boston; Caucus of American Indian, Alaska Native and Native Hawaiian Psychiatrists, American Psychiatric Association, Washington, DC (Roessel); Department of Psychiatry, Anschutz Medical Campus, University of Colorado, Aurora (Shore)
| | - Francisco A Moreno
- Center for Applied Behavioral Health Policy, Watts College of Public Service and Community Solutions, Arizona State University, Phoenix (Mendoza, Gallegos); College of Medicine, University of Arizona Health Sciences, Tucson and Phoenix (Moreno); College of Medicine, University of Arizona Health Sciences Center, Tucson (Hishaw); University of California, San Francisco, Medical School, San Francisco (Gaw); Boston Medical Center, School of Medicine (Fortuna), and Wheelock College of Education and Human Development (Skubel, Porche), all at Boston University, Boston; Caucus of American Indian, Alaska Native and Native Hawaiian Psychiatrists, American Psychiatric Association, Washington, DC (Roessel); Department of Psychiatry, Anschutz Medical Campus, University of Colorado, Aurora (Shore)
| | - G Alexander Hishaw
- Center for Applied Behavioral Health Policy, Watts College of Public Service and Community Solutions, Arizona State University, Phoenix (Mendoza, Gallegos); College of Medicine, University of Arizona Health Sciences, Tucson and Phoenix (Moreno); College of Medicine, University of Arizona Health Sciences Center, Tucson (Hishaw); University of California, San Francisco, Medical School, San Francisco (Gaw); Boston Medical Center, School of Medicine (Fortuna), and Wheelock College of Education and Human Development (Skubel, Porche), all at Boston University, Boston; Caucus of American Indian, Alaska Native and Native Hawaiian Psychiatrists, American Psychiatric Association, Washington, DC (Roessel); Department of Psychiatry, Anschutz Medical Campus, University of Colorado, Aurora (Shore)
| | - Albert C Gaw
- Center for Applied Behavioral Health Policy, Watts College of Public Service and Community Solutions, Arizona State University, Phoenix (Mendoza, Gallegos); College of Medicine, University of Arizona Health Sciences, Tucson and Phoenix (Moreno); College of Medicine, University of Arizona Health Sciences Center, Tucson (Hishaw); University of California, San Francisco, Medical School, San Francisco (Gaw); Boston Medical Center, School of Medicine (Fortuna), and Wheelock College of Education and Human Development (Skubel, Porche), all at Boston University, Boston; Caucus of American Indian, Alaska Native and Native Hawaiian Psychiatrists, American Psychiatric Association, Washington, DC (Roessel); Department of Psychiatry, Anschutz Medical Campus, University of Colorado, Aurora (Shore)
| | - Lisa R Fortuna
- Center for Applied Behavioral Health Policy, Watts College of Public Service and Community Solutions, Arizona State University, Phoenix (Mendoza, Gallegos); College of Medicine, University of Arizona Health Sciences, Tucson and Phoenix (Moreno); College of Medicine, University of Arizona Health Sciences Center, Tucson (Hishaw); University of California, San Francisco, Medical School, San Francisco (Gaw); Boston Medical Center, School of Medicine (Fortuna), and Wheelock College of Education and Human Development (Skubel, Porche), all at Boston University, Boston; Caucus of American Indian, Alaska Native and Native Hawaiian Psychiatrists, American Psychiatric Association, Washington, DC (Roessel); Department of Psychiatry, Anschutz Medical Campus, University of Colorado, Aurora (Shore)
| | - Anna Skubel
- Center for Applied Behavioral Health Policy, Watts College of Public Service and Community Solutions, Arizona State University, Phoenix (Mendoza, Gallegos); College of Medicine, University of Arizona Health Sciences, Tucson and Phoenix (Moreno); College of Medicine, University of Arizona Health Sciences Center, Tucson (Hishaw); University of California, San Francisco, Medical School, San Francisco (Gaw); Boston Medical Center, School of Medicine (Fortuna), and Wheelock College of Education and Human Development (Skubel, Porche), all at Boston University, Boston; Caucus of American Indian, Alaska Native and Native Hawaiian Psychiatrists, American Psychiatric Association, Washington, DC (Roessel); Department of Psychiatry, Anschutz Medical Campus, University of Colorado, Aurora (Shore)
| | - Michelle V Porche
- Center for Applied Behavioral Health Policy, Watts College of Public Service and Community Solutions, Arizona State University, Phoenix (Mendoza, Gallegos); College of Medicine, University of Arizona Health Sciences, Tucson and Phoenix (Moreno); College of Medicine, University of Arizona Health Sciences Center, Tucson (Hishaw); University of California, San Francisco, Medical School, San Francisco (Gaw); Boston Medical Center, School of Medicine (Fortuna), and Wheelock College of Education and Human Development (Skubel, Porche), all at Boston University, Boston; Caucus of American Indian, Alaska Native and Native Hawaiian Psychiatrists, American Psychiatric Association, Washington, DC (Roessel); Department of Psychiatry, Anschutz Medical Campus, University of Colorado, Aurora (Shore)
| | - Mary Hasbah Roessel
- Center for Applied Behavioral Health Policy, Watts College of Public Service and Community Solutions, Arizona State University, Phoenix (Mendoza, Gallegos); College of Medicine, University of Arizona Health Sciences, Tucson and Phoenix (Moreno); College of Medicine, University of Arizona Health Sciences Center, Tucson (Hishaw); University of California, San Francisco, Medical School, San Francisco (Gaw); Boston Medical Center, School of Medicine (Fortuna), and Wheelock College of Education and Human Development (Skubel, Porche), all at Boston University, Boston; Caucus of American Indian, Alaska Native and Native Hawaiian Psychiatrists, American Psychiatric Association, Washington, DC (Roessel); Department of Psychiatry, Anschutz Medical Campus, University of Colorado, Aurora (Shore)
| | - Jay Shore
- Center for Applied Behavioral Health Policy, Watts College of Public Service and Community Solutions, Arizona State University, Phoenix (Mendoza, Gallegos); College of Medicine, University of Arizona Health Sciences, Tucson and Phoenix (Moreno); College of Medicine, University of Arizona Health Sciences Center, Tucson (Hishaw); University of California, San Francisco, Medical School, San Francisco (Gaw); Boston Medical Center, School of Medicine (Fortuna), and Wheelock College of Education and Human Development (Skubel, Porche), all at Boston University, Boston; Caucus of American Indian, Alaska Native and Native Hawaiian Psychiatrists, American Psychiatric Association, Washington, DC (Roessel); Department of Psychiatry, Anschutz Medical Campus, University of Colorado, Aurora (Shore)
| | - Anthony Gallegos
- Center for Applied Behavioral Health Policy, Watts College of Public Service and Community Solutions, Arizona State University, Phoenix (Mendoza, Gallegos); College of Medicine, University of Arizona Health Sciences, Tucson and Phoenix (Moreno); College of Medicine, University of Arizona Health Sciences Center, Tucson (Hishaw); University of California, San Francisco, Medical School, San Francisco (Gaw); Boston Medical Center, School of Medicine (Fortuna), and Wheelock College of Education and Human Development (Skubel, Porche), all at Boston University, Boston; Caucus of American Indian, Alaska Native and Native Hawaiian Psychiatrists, American Psychiatric Association, Washington, DC (Roessel); Department of Psychiatry, Anschutz Medical Campus, University of Colorado, Aurora (Shore)
| |
Collapse
|
5
|
Moreno FA. Diversity, Equity, and Inclusion in Psychiatry. Focus (Am Psychiatr Publ) 2020; 18:1. [PMID: 32047390 PMCID: PMC7011219 DOI: 10.1176/appi.focus.18101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- Francisco A Moreno
- Dr. Moreno is Associate Vice President for Diversity and Inclusion, University of Arizona Health Sciences, Tucson
| |
Collapse
|
6
|
Ranjbar N, Erb M, Mohammad O, Moreno FA. Trauma-Informed Care and Cultural Humility in the Mental Health Care of People From Minoritized Communities. Focus (Am Psychiatr Publ) 2020; 18:8-15. [PMID: 32047392 PMCID: PMC7011220 DOI: 10.1176/appi.focus.20190027] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The prevalence and impact of trauma constitute a public health crisis that is complicated by the cultural heterogeneity of contemporary society and a higher rate of trauma among individuals from minoritized communities. A trauma-informed care approach can facilitate improved treatment of those who have experienced trauma, and trauma-informed care is increasingly viewed as potentially beneficial for all patients. This article outlines general principles of trauma-informed care and ways to enact it. Because the situations in which trauma arises, the ways in which it is conceptualized, and how patients respond to it are influenced by both culture and individual factors, a cultural humility approach is also described and recommended. Psychiatrists can navigate the complex terrain of cultures and social backgrounds in the clinical encounter and can promote healing when treating patients who have experienced trauma by adopting a trauma-informed care approach and an attitude of cultural humility.
Collapse
Affiliation(s)
- Noshene Ranjbar
- Department of Psychiatry, University of Arizona, Tucson (Ranjbar, Moreno); The Center for Mind-Body Medicine, Washington, D.C. (Erb); Department of Psychiatry, University of Massachusetts-Baystate, Springfield (Mohammad)
| | - Matt Erb
- Department of Psychiatry, University of Arizona, Tucson (Ranjbar, Moreno); The Center for Mind-Body Medicine, Washington, D.C. (Erb); Department of Psychiatry, University of Massachusetts-Baystate, Springfield (Mohammad)
| | - Othman Mohammad
- Department of Psychiatry, University of Arizona, Tucson (Ranjbar, Moreno); The Center for Mind-Body Medicine, Washington, D.C. (Erb); Department of Psychiatry, University of Massachusetts-Baystate, Springfield (Mohammad)
| | - Francisco A Moreno
- Department of Psychiatry, University of Arizona, Tucson (Ranjbar, Moreno); The Center for Mind-Body Medicine, Washington, D.C. (Erb); Department of Psychiatry, University of Massachusetts-Baystate, Springfield (Mohammad)
| |
Collapse
|
7
|
Abstract
The increasing diversity of America requires a workforce that is able to serve the mental health needs of individuals from multiple backgrounds, with a culturally proficient, inclusive, and affirming approach. To accomplish this, clinicians must be mindful of the multiple challenges presented by social determinants of mental health and access to care; the role of culture in wellness protection, mental illness expression, symptom attribution, and help seeking; the impact of provider factors, such as availability and cultural and linguistic congruence and proficiency; and the interaction of clinician and patient, who are with increasing frequency members of differing identity groups. The authors highlight the central role of clinical providers, academic institutions, and service organizations to advance health equity through training and commitment to increase high-quality services that are available, accessible, affordable, and acceptable, improving the care of all individuals.
Collapse
Affiliation(s)
- Francisco A Moreno
- Department of Psychiatry, University of Arizona College of Medicine-Tucson, Tucson
| | - Jasleen Chhatwal
- Department of Psychiatry, University of Arizona College of Medicine-Tucson, Tucson
| |
Collapse
|
8
|
Gerald JK, Moreno FA. Asthma and Depression: It's Complicated. J Allergy Clin Immunol Pract 2016; 4:74-5. [PMID: 26772927 DOI: 10.1016/j.jaip.2015.11.020] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Received: 11/12/2015] [Accepted: 11/13/2015] [Indexed: 10/22/2022]
Affiliation(s)
- Joe K Gerald
- Mel and Enid Zuckerman College of Public Health, The University of Arizona, Tucson, Ariz.
| | - Francisco A Moreno
- Department of Psychiatry, University of Arizona College of Medicine, Tucson, Ariz
| |
Collapse
|
9
|
Moreno FA, Erickson RP, Garriock HA, Gelernter J, Mintz J, Oas-Terpstra J, Davies MA, Delgado PL. Association Study of Genotype by Depressive Response during Tryptophan Depletion in Subjects Recovered from Major Depression. Mol Neuropsychiatry 2015; 1:165-174. [PMID: 26528486 DOI: 10.1159/000439114] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
PURPOSE The brief and reversible mood response to acute tryptophan (TRP) depletion (ATD) is being studied as a trait marker in subjects considered at risk for major depression (MD). PROCEDURES ATD was administered to 64 subjects (54 European-Americans, and10 from other races) with personal and family history of MD. They were in remission and had been medication-free for at least three months. Subjects received an active and sham condition in a random assignment, double-blind crossover design. They were genotyped for serotonin-related candidate genes, and mood response was quantified with the Hamilton Depression Rating Scale (HDRS). Data were analyzed using Poisson regression with repeated measures and latent trajectory models. RESULTS Compared to the sham control, active ATD caused modest depressive changes showing significant main effects of test condition (χ2=5.14, df=1, p=0.023) and time (χ2=12.22, df=3, p=0.007), but no significant interaction of time and test condition. Latent trajectory analysis revealed two groups, identified as depletion responders and non-responders. Those with the HTR2A rs6313 CC genotype had significantly higher HDRS scores during ATD (χ2=11.72, df=1, p=.0006). CONCLUSIONS AND MESSAGE ATD may help the identification of biological subtypes of MD. These data are consistent with imaging reports implicating 5-HT2A receptor function in ATD phenotypes.
Collapse
Affiliation(s)
- Francisco A Moreno
- Department of Psychiatry, College of Medicine, The University of Arizona Health Sciences Center, USA
| | - Robert P Erickson
- Department of Pediatrics, College of Medicine, The University of Arizona Health Sciences Center, USA
| | - Holly A Garriock
- Division of Translational Research (DTR), National Institute of Mental Health, USA
| | - Joel Gelernter
- Department of Psychiatry, Yale University School of Medicine, VA Connecticut Health Care Center, USA
| | - Jim Mintz
- Department of Psychiatry, University of Texas Health Sciences Center San Antonio, USA
| | - Jennifer Oas-Terpstra
- Department of Physiology, College of Medicine, The University of Arizona Health Sciences Center, USA
| | - Marilyn A Davies
- Health and Community Systems, University of Pittsburgh School of Nursing, USA
| | - Pedro L Delgado
- Department of Psychiatry, University of Arkansas for Medical Sciences, USA
| |
Collapse
|
10
|
Hasselmo K, Sbarra DA, O'Connor MF, Moreno FA. Psychological distress following marital separation interacts with a polymorphism in the serotonin transporter gene to predict cardiac vagal control in the laboratory. Psychophysiology 2015; 52:736-44. [PMID: 25630596 DOI: 10.1111/psyp.12409] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Accepted: 12/20/2014] [Indexed: 12/16/2022]
Abstract
Marital separation is linked to negative mental and physical health; however, the strength of this link may vary across people. This study examined changes in respiratory sinus arrhythmia (RSA), used to assess cardiac vagal control, in recently separated adults (N = 79; M time since separation = 3.5 months). When reflecting on the separation, self-reported psychological distress following the separation interacted with a polymorphism in the serotonin transporter gene (5-HTTLPR) and a relevant single nucleotide polymorphism (SNP), rs25531, to predict RSA. Among people reporting emotional difficulties after the separation, those who were homozygous for the short allele had lower RSA levels while reflecting on their relationship than other genotypes. The findings, although limited by the relatively small sample size, are discussed in terms of how higher-sensitivity genotypes may interact with psychological responses to stress to alter physiology.
Collapse
Affiliation(s)
- Karen Hasselmo
- Department of Psychology, University of Arizona, Tucson, Arizona, USA
| | - David A Sbarra
- Department of Psychology, University of Arizona, Tucson, Arizona, USA
| | | | - Francisco A Moreno
- Department of Psychiatry, University of Arizona College of Medicine, Tucson, Arizona, USA
| |
Collapse
|
11
|
Moreno FA, Chong J, Dumbauld J, Humke M, Byreddy S. Use of standard Webcam and Internet equipment for telepsychiatry treatment of depression among underserved Hispanics. Psychiatr Serv 2012; 63:1213-7. [PMID: 23026854 DOI: 10.1176/appi.ps.201100274] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
OBJECTIVE Depression affects nearly one in five Americans at some time in their life, causing individual suffering and financial cost. The Internet has made it possible to deliver telemedicine care economically to areas and populations with limited access to specialist or culturally and linguistically congruent care. METHODS This study compared the effectiveness for Hispanic patients of depression treatment provided by a psychiatrist through Internet videoconferencing (Webcam intervention) and treatment as usual by a primary care provider. Adults (N=167) with a diagnosis of depression were recruited from a community clinic and were randomly assigned to treatment condition. Webcam participants met remotely each month with the psychiatrist, and treatment-as-usual patients received customary care from their primary care providers, all for six months. At baseline and three and six months, analyses of variance tested differences between conditions in scores on depression rating scales and quality-of-life and functional ability measures. RESULTS All participants experienced an improvement in depression symptoms. Ratings on the Montgomery-Åsberg Depression Rating Scale by clinicians blind to treatment group and self-ratings on the nine-item Patient Health Questionnaire, Quality of Life Enjoyment and Satisfaction Questionnaire, and Sheehan Disability Scale showed a significant main effect of time. On all four measures, a significant interaction of time by intervention favoring the Webcam group was noted. DISCUSSION Results suggest that telepsychiatry delivered through the Internet utilizing commercially available domestic Webcams and standard Internet and computer equipment is effective and acceptable. Use of this technology may help close the gap in access to culturally and linguistically congruent specialists.
Collapse
Affiliation(s)
- Francisco A Moreno
- Department of Psychiatry, University of Arizona, 1501 N. Campbell Ave., 7- OPC, Tucson, AZ 85724, USA.
| | | | | | | | | |
Collapse
|
12
|
Chong J, Reinschmidt KM, Moreno FA. Symptoms of depression in a Hispanic primary care population with and without chronic medical illnesses. Prim Care Companion J Clin Psychiatry 2012; 12. [PMID: 20944771 DOI: 10.4088/pcc.09m00846blu] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2009] [Accepted: 08/14/2009] [Indexed: 10/19/2022]
Abstract
OBJECTIVE To describe somatic and psychiatric symptoms reported by Hispanic primary care patients with and without depression and/or chronic medical illnesses. METHOD Adult Hispanic patients (n = 104) in a Mobile Health Program in underserved southern Arizona participated in a survey conducted between September 2006 and February 2007 to obtain information about the somatic and psychiatric symptoms that they were experiencing. They were asked to rate the severity of their symptoms listed in the depression screen Personal Health Questionnaire-9 (PHQ-9), the Symptom Checklist-90-Revised (SCL-90-R), and 5 new symptoms described by patients in focus groups conducted in the first phase of the project. Patients were categorized as depressed if their PHQ-9 scores were 10 or above, and they were further categorized as having or not having chronic illnesses based on self-report. Analyses of variance were conducted for each SCL-90-R symptom dimension to compare across the 4 groups (group 1: not depressed and not medically ill; group 2: medically ill but not depressed; group 3: depressed but not medically ill; and group 4: depressed and medically ill). RESULTS Patients with chronic medical illnesses comorbid with depression were found to report significantly more somatic symptoms than those with only chronic medical illnesses or depression alone (P ≤ .001). They also reported significantly more psychopathology than patients with depression alone (P ≤ .05 or better). CONCLUSIONS Patients with medical illnesses comorbid with depression are more likely to exhibit psychopathology than patients with medical illnesses or depression alone.
Collapse
Affiliation(s)
- Jenny Chong
- Native American Research and Training Center, Department of Family and Community Medicine, University of Arizona, Tucson, AZ, USA.
| | | | | |
Collapse
|
13
|
Breitborde NJK, Moreno FA, Mai-Dixon N, Peterson R, Durst L, Bernstein B, Byreddy S, McFarlane WR. Multifamily group psychoeducation and cognitive remediation for first-episode psychosis: a randomized controlled trial. BMC Psychiatry 2011; 11:9. [PMID: 21226941 PMCID: PMC3030530 DOI: 10.1186/1471-244x-11-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2010] [Accepted: 01/12/2011] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Multifamily group psychoeducation (MFG) has been shown to reduce relapse rates among individuals with first-episode psychosis. However, given the cognitive demands associated with participating in this intervention (e.g., learning and applying a structured problem-solving activity), the cognitive deficits that accompany psychotic disorders may limit the ability of certain individuals to benefit from this intervention. Thus, the goal of this study is to examine whether individuals with first-episode psychosis who participate simultaneously in MFG and cognitive remediation--an intervention shown to improve cognitive functioning among individuals with psychotic disorders--will be less likely to experience a relapse than individuals who participate in MFG alone. METHODS/DESIGN Forty individuals with first-episode psychosis and their caregiving relative will be recruited to participate in this study. Individuals with first-episode psychosis will be randomized to one of two conditions: (i) MFG with concurrent participation in cognitive remediation or (ii) MFG alone. The primary outcome for this study is relapse of psychotic symptoms. We will also examine secondary outcomes among both individuals with first-episode psychosis (i.e., social and vocational functioning, health-related quality of life, service utilization, independent living status, and cognitive functioning) and their caregiving relatives (i.e., caregiver burden, anxiety, and depression) DISCUSSION Cognitive remediation offers the possibility of ameliorating a specific deficit (i.e., deficits in cognitive functioning) that often accompanies psychotic symptoms and may restrict the magnitude of the clinical benefits derived from MFG. TRIAL REGISTRATION ClinicalTrials (NCT): NCT01196286.
Collapse
Affiliation(s)
- Nicholas JK Breitborde
- Department of Psychiatry, University of Arizona, 1501 N. Campbell Ave., PO Box 245002, Tucson, AZ, 85724-5002, USA,Department of Psychiatry, University Physicians Hospital, 2800 E. Ajo Way, Tucson, Arizona, 85713, USA
| | - Francisco A Moreno
- Department of Psychiatry, University of Arizona, 1501 N. Campbell Ave., PO Box 245002, Tucson, AZ, 85724-5002, USA,Department of Psychiatry, University Physicians Hospital, 2800 E. Ajo Way, Tucson, Arizona, 85713, USA
| | - Natalie Mai-Dixon
- Department of Psychiatry, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, New York, 14642, USA
| | - Rachele Peterson
- Department of Psychiatry, University of Arizona, 1501 N. Campbell Ave., PO Box 245002, Tucson, AZ, 85724-5002, USA
| | - Linda Durst
- Department of Psychiatry, University of Arizona, 1501 N. Campbell Ave., PO Box 245002, Tucson, AZ, 85724-5002, USA,Department of Psychiatry, University Physicians Hospital, 2800 E. Ajo Way, Tucson, Arizona, 85713, USA
| | - Beth Bernstein
- Department of Psychiatry, University of Arizona, 1501 N. Campbell Ave., PO Box 245002, Tucson, AZ, 85724-5002, USA,Department of Psychiatry, University Physicians Hospital, 2800 E. Ajo Way, Tucson, Arizona, 85713, USA
| | - Seenaiah Byreddy
- Department of Psychiatry, University of Arizona, 1501 N. Campbell Ave., PO Box 245002, Tucson, AZ, 85724-5002, USA
| | - William R McFarlane
- Department of Psychiatry, Maine Medical Center, 295 Park Ave., Portland, Maine, 04102, USA
| |
Collapse
|
14
|
Moreno FA, Parkinson D, Palmer C, Castro WL, Misiaszek J, El Khoury A, Mathé AA, Wright R, Delgado PL. CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls. Eur Neuropsychopharmacol 2010; 20:18-24. [PMID: 19896342 PMCID: PMC2794896 DOI: 10.1016/j.euroneuro.2009.10.003] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2005] [Revised: 08/25/2009] [Accepted: 10/07/2009] [Indexed: 12/21/2022]
Abstract
The purpose of this study was to examine the differential effects of acute tryptophan (TRP) depletion vs. sham condition on plasma, cerebrospinal fluid (CSF) biochemical parameters, and mood in the following three subject groups: (1) nine antidepressant-free individuals with remitted depression, (2) eight paroxetine-treated individuals with recently remitted depression, and (3) seven healthy controls. Plasma TRP decreased during TRP depletion and increased during sham condition (p<.01). CSF TRP and 5-hydroxyindoleacetic acid were lower during TRP depletion than sham condition (p<.01 each). During TRP depletion, CSF TRP correlated significantly with the plasma sum of large neutral amino acids (SigmaLNAA) (R=-.52, p=.01), but did not significantly correlate with plasma TRP (R=.15, p=.52). The correlation between CSF TRP and ratio of TRP to SigmaLNAA was R=.41 and p=.06 during TRP depletion, and R=-.44 and p=.04 during sham condition. A negative correlation trend was observed between CSF-TRP levels and peak Hamilton Depression Rating Scale scores during TRP depletion in patients recovered from depression (R=-.45, p=.07), but not in healthy controls (R=-.01, p=.98). CSF neuropeptide Y was higher during TRP depletion than sham condition (t=1.75, p<.10). These results illustrate the importance of assessing plasma SigmaLNAA when using the TRP depletion paradigm. The use of a single CSF sampling technique although practical may result in data acquisition limitations.
Collapse
Affiliation(s)
- Francisco A Moreno
- Department of Psychiatry, College of Medicine, The University of Arizona Health Sciences Center, 1501 N. Campbell Ave. 7-OPC, Tucson, AZ 85724, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Bismark AW, Moreno FA, Stewart JL, Towers DN, Coan JA, Oas J, Erickson RP, Allen JJB. Polymorphisms of the HTR1a allele are linked to frontal brain electrical asymmetry. Biol Psychol 2009; 83:153-8. [PMID: 20025927 DOI: 10.1016/j.biopsycho.2009.12.002] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2009] [Revised: 12/09/2009] [Accepted: 12/09/2009] [Indexed: 12/25/2022]
Abstract
Polymorphic variations in genes related to serotonin synthesis, transport, recognition, or degradation may convey subtle changes in serotonin system architecture that may place an individual at risk for psychopathology when faced with life stressors. The relationship between three key serotonin alleles and frontal brain electrical asymmetry, a putative endophenotype of depression, was examined. Risk alleles were hypothesized to predict relatively greater right frontal brain activity regardless of current clinical state. A sample of 313 college-age individuals, spanning a range of depressive severity from no symptomotology to clinically meaningful levels, participated. Resting encephalographic (EEG) activity was recorded from 64 scalp sites on four occasions separated by at least 24h (two 8-min recording sessions occurring at each occasion). Alpha power asymmetry scores between homologous sites were calculated for each session and then averaged to form a trait metric of asymmetry for each pair. PCR based genotyping was conducted for the HTR1a, HTR2a, and HTTLPR genes. Variations in the HTR1a gene were related to trait EEG asymmetry, regardless of any history of depression. Compared to subjects with at least one non-risk allele, subjects with homozygous HTR1A risk alleles had significantly greater relative right frontal activity at sites F7/F8, F5/F6, and F1/F2. In conclusion, variation in HTR1a can influence trait level brain activity, which may ultimately be indicative of risk for psychopathology.
Collapse
|
16
|
Allen JJ, McKnight KM, Moreno FA, Demaree HA, Delgado PL. Alteration of frontal EEG asymmetry during tryptophan depletion predicts future depression. J Affect Disord 2009; 115:189-95. [PMID: 18801582 PMCID: PMC2688527 DOI: 10.1016/j.jad.2008.08.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2005] [Revised: 07/16/2008] [Accepted: 08/05/2008] [Indexed: 11/24/2022]
Abstract
BACKGROUND Tryptophan depletion (TD) reduces brain serotonin and may induce acute depressive symptomatology, especially among those with a history of Major Depression. Depressive response to TD among euthymic patients with a history of depression also predicts future depression. Better prediction might result by assessing a putative endophenotype for depressive risk, frontal electroencephalographic (EEG) asymmetry, in the context of TD. METHOD Nine euthymic history-positive participants and nine controls were administered TD. Symptomatic and EEG frontal asymmetry data were collected for 6 h following TD, and clinical status was followed for the next 12 months. RESULTS The magnitude of TD-induced change in frontal EEG asymmetry significantly predicted the development of depression during the ensuing six to twelve months, and with greater sensitivity than symptomatic response. LIMITATIONS The results are tempered by the small sample size. CONCLUSIONS Despite the limited sample size, these preliminary results suggest that TD-induced changes in frontal EEG asymmetry may provide a more sensitive indicator of risk for imminent depression than symptomatic response to TD.
Collapse
Affiliation(s)
| | | | - Francisco A. Moreno
- Department of Psychiatry; College of Medicine; The University of Arizona Health Sciences Center, Tucson, AZ
| | - Heath A. Demaree
- Department of Psychology; Case Western Reserve University; Cleveland, OH
| | - Pedro L. Delgado
- Department of Psychiatry; University of Texas Health Science Center, San Antonio, TX
| |
Collapse
|
17
|
Abstract
BACKGROUND Anecdotal reports suggest that psychedelic agents may relieve symptoms of obsessive-compulsive disorder (OCD). This modified double-blind study investigated the safety, tolerability, and clinical effects of psilocybin, a potent 5-HT(1A) and 5-HT(2A/2C) agonist, in patients with OCD. METHOD Nine subjects with DSM-IV-defined OCD and no other current major psychiatric disorder participated in up to 4 single-dose exposures to psilocybin in doses ranging from sub-hallucinogenic to frankly hallucinogenic. Low (100 microg/kg), medium (200 microg/kg), and high (300 microg/kg) doses were assigned in that order, and a very low dose (25 microg/kg) was inserted randomly and in double-blind fashion at any time after the first dose. Testing days were separated by at least 1 week. Each session was conducted over an 8-hour period in a controlled environment in an outpatient clinic; subjects were then transferred to a psychiatric inpatient unit for overnight observation. The Yale-Brown Obsessive Compulsive Scale (YBOCS) and a visual analog scale measuring overall obsessive-compulsive symptom severity were administered at 0, 4, 8, and 24 hours post-ingestion. The Hallucinogen Rating Scale was administered at 8 hours, and vital signs were recorded at 0, 1, 4, 8, and 24 hours after ingestion. The study was conducted from November 2001 to November 2004. RESULTS Nine subjects were administered a total of 29 psilocybin doses. One subject experienced transient hypertension without relation to anxiety or somatic symptoms, but no other significant adverse effects were observed. Marked decreases in OCD symptoms of variable degrees were observed in all subjects during 1 or more of the testing sessions (23%-100% decrease in YBOCS score). Repeated-measures analysis of variance for all YBOCS values revealed a significant main effect of time on Wilks lambda (F = 9.86, df = 3,3; p = .046), but no significant effect of dose (F = 2.25, df = 3,3; p = .261) or interaction of time and dose (F = 0.923, df = 9,45; p = .515). Improvement generally lasted past the 24-hour timepoint. CONCLUSIONS In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.
Collapse
|
18
|
Abstract
OBJECTIVE To assess the efficacy of acupuncture as an intervention for major depressive disorder (MDD). METHOD Acupuncture was examined in 151 patients with MDD (DSM-IV) who were randomly assigned to 1 of 3 groups in a double-blind randomized controlled trial. The specific intervention involved Traditional Chinese Medicine (TCM)-style acupuncture with manual stimulation for depression; the control conditions consisted of (1) a nonspecific intervention using a comparable number of legitimate acupuncture points not specifically targeted to depressive symptoms and (2) a waitlist condition, which involved waiting without intervention for 8 weeks. After 8 weeks, all patients received the depression-specific acupuncture. Each 8-week intervention regimen consisted of 12 acupuncture sessions delivered in an acupuncturist's office in the community. The primary outcome measure was the 17-item Hamilton Rating Scale for Depression. The study was conducted from February 1998 to April 2002. RESULTS Twenty patients terminated treatment before the completion of the 8-week intervention (13%) but not differentially by study group. Random regression models of the intent-to-treat sample revealed that although patients receiving acupuncture improved more than those awaiting intervention, no evidence of differential efficacy of the depression-specific over nonspecific intervention was found. Response rates in acupuncture-treated patients were relatively low after 8 weeks (22% and 39% for specific and nonspecific intervention groups, respectively), with the response rate after the entire 16-week trial reaching 50%. CONCLUSION Although TCM manual acupuncture is a well-tolerated intervention, results fail to support its efficacy as a monotherapy for MDD. It can't be ruled out that factors unique to the implementation of acupuncture in this research study may have limited the efficacy of interventions compared to those provided in naturalistic settings. CLINICAL TRIALS REGISTRATION ClinicalTrials.gov identifier NCT00010517.
Collapse
Affiliation(s)
- John J B Allen
- Department of Psychology, University of Arizona, Tucson 85721-0068, USA.
| | | | | | | | | | | |
Collapse
|
19
|
Abstract
OBJECTIVE Although sex differences in the prevalence of depression are well known, the effects of sex on the underlying mechanisms of illness and on antidepressant action remain less clear. Tryptophan depletion and catecholamine depletion (via alpha-methylparatyrosine [AMPT] administration) are broadly utilized methods for studying the effects of the safe and transient reduction of serotonin and catecholamine neuro-transmission, respectively. The present study assessed the effects of sex on the mood response during acute monoamine depletion. METHOD Data on Hamilton Rating Scale for Depression (HAM-D) scores during depletion tests were analyzed retrospectively in 59 subjects (41 women, 18 men) who underwent tryptophan depletion and 39 subjects (25 women, 14 men) who underwent catecholamine depletion. All subjects were in remission from a DSM-IV-defined major depressive episode. Data reviewed included subjects enrolled between November 1993 and November 1997. RESULTS Significant increases in HAM-D scores were observed in response to both depletion procedures, with a similar magnitude of change. Analysis of variance with repeated measures of HAM-D scores revealed a significant main effect of time for tryptophan depletion (F = 7.31, df = 3, p < .01) and for catecholamine depletion (F = 9.61, df = 4, p < .01). Time-by-sex interaction was significant for tryptophan depletion (F = 4.04, df = 3, p = .01), but not for catecholamine depletion (F = 0.75, df = 4, p = .57). Depressive symptoms were significantly greater in women during tryptophan depletion (t test p < .01), while no significant sex differences were found during catecholamine depletion. CONCLUSIONS These findings suggest that the effect of sex in depressive vulnerability may be related to differential sex effects in monoaminergic function.
Collapse
Affiliation(s)
- Francisco A Moreno
- Department of Psychiatry, College of Medicine, University of Arizona Health Sciences Center, Tucson 85724, USA.
| | | | | | | |
Collapse
|
20
|
Garriock HA, Delgado P, Kling MA, Carpenter LL, Burke M, Burke WJ, Schwartz T, Marangell LB, Husain M, Erickson RP, Moreno FA. Number of risk genotypes is a risk factor for major depressive disorder: a case control study. Behav Brain Funct 2006; 2:24. [PMID: 16822313 PMCID: PMC1526442 DOI: 10.1186/1744-9081-2-24] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2006] [Accepted: 07/05/2006] [Indexed: 01/16/2023] Open
Abstract
Background The objective of the study was to determine the genetic basis of Major Depressive Disorder, and the capacity to respond to antidepressant treatment. An association study of 21 candidate polymorphisms relevant to monoamine function and the mechanism of antidepressant response was conducted in 3 phenotypically distinct samples: a group with chronic or recurrent depression unable to respond to antidepressants (non-responders) (n = 58), a group capable of symptomatic improvement with or without treatment (responders) (n = 39), and volunteer controls (n = 85). The responders and non-responders constituted a larger group of depressed subjects. Methods A candidate gene approach was employed to asses the genetics basis of Major Depressive Disorder. The genotypic frequencies of selected polymorphisms were compared between the controls and depressed subjects. To asses the genetics basis of the capacity to respond to antidepressant treatment, the responders were compared to the non-responders. Candidate genes were chosen based on functional studies and proximity to whole genome linkage findings in the literature. Risk genotypes were identified by previous functional studies and association studies. Results A statistically significant difference in genotype frequency for the SLC6A4 intron 2 VNTR was detected between the subjects with a history of depression and controls (p = 0.004). Surprisingly, a statistically significant difference was detected between responders and non-responders for the DRD4 exon III VNTR genotype frequencies (p = 0.009). Furthermore, a difference between the controls and depressed subjects as well as between the controls and non-responders was detected for the number and distribution of risk genotypes in each group. Conclusion An association between several monoamine-related genes and Major Depressive Disorder is supported. The data suggest that the two depressive phenotypes are genetically different, inferring that the genetic basis for the capacity to respond to standard antidepressant treatment, and the genetic susceptibility to Major Depressive Disorder may be independent. In addition, a proof of concept is provided demonstrating that the number of risk genotypes may be an indication of susceptibility of major depressive disorder and the severity of the disorder.
Collapse
Affiliation(s)
- Holly A Garriock
- Interdisciplinary Program in Genetics, Department of Psychiatry, University of Arizona, Tucson, AZ, USA
- Department of Psychiatry, College of Medicine, The University of Arizona Health Sciences Center, 1501 N. Campbell Ave. 7-OPC, Tucson, Arizona 85724, Phone (520) 626-6509, Fax (520) 626-6050, USA
| | - Pedro Delgado
- Department of Psychiatry, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA
| | - Mitchel A Kling
- Neuroscience Center, National Institute of Mental Health, Rockville, MD, USA
| | - Linda L Carpenter
- Department of Psychiatry, Butler Hospital Brown University, Providence, RI, USA
| | - Michael Burke
- Department of Psychiatry and Behavioral Sciences, Kansas University School of Medicine, Witchita, KS, USA
| | - William J Burke
- Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE, USA
| | - Thomas Schwartz
- Department of Psychiatry, New York State School of Medicine, Purchase, NY, USA
| | | | - Mustafa Husain
- Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Robert P Erickson
- Interdisciplinary Program in Genetics, Department of Psychiatry, University of Arizona, Tucson, AZ, USA
- Departments of Pediatrics and Molecular & Cellular Biology, University of Arizona, Tucson, AZ, USA
| | - Francisco A Moreno
- Department of Psychiatry, College of Medicine, The University of Arizona Health Sciences Center, 1501 N. Campbell Ave. 7-OPC, Tucson, Arizona 85724, Phone (520) 626-6509, Fax (520) 626-6050, USA
| |
Collapse
|
21
|
Garriock HA, Allen JJB, Delgado P, Nahaz Z, Kling MA, Carpenter L, Burke M, Burke W, Schwartz T, Marangell LB, Husain M, Erickson RP, Moreno FA. Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry 2005; 10:976-7. [PMID: 16027738 DOI: 10.1038/sj.mp.4001712] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
22
|
Abstract
BACKGROUND Carnitine facilitates the transport of long-chain fatty acids across the mitochondria for beta oxidation, and the removal of potentially toxic acylcoenzyme-A metabolites from the inner aspect of mitochondrion as acylcarnitines. Previous studies suggest a significant decrease in carnitine concentrations and changes in the ratio of acylcarnitine to free carnitine in seizure-disoriented patients treated with valproic acid (VPA), which may lead to clinical manifestations of carnitine deficiency. This study sought to explore whether the same decrease in plasma free carnitine and increase in acylcarnitines are seen when VPA is used in the treatment of patients with psychiatric disease. METHOD Thirty psychiatric patients treated with VPA for at least six months were selected for the study and granted informed consent for participation. Exclusion criteria included liver disorder or pancreatitis, metabolic defects known to affect plasma carnitine levels, or noncompliance with VPA regimen. Plasma free carnitine, total carnitine, VPA, and amylase levels were determined, and liver function tests (LFTs) were performed. Pearson correlations were conducted between VPA levels, levels and ratios of carnitines, as well as LFTs and amylase levels. RESULTS Plasma free and total carnitine levels were lower than the reported normal range for the laboratory performing the assay, and the ratio of acylcarnitine to free carnitine was increased. There was a significant positive correlation of VPA levels and acylcarnitine-free carnitine ratio, a trend toward significance between VPA levels and acylcarnitine levels, and a marginal negative correlation between VPA levels and free carnitine levels. VPA levels correlated also with several LFTs and acylcarnitine levels. Octanoyl carnitine and acylcarnitine levels, as well as acylcarnitine-free carnitine and octanoyl-free carnitine ratios, correlated significantly with amylase levels. CONCLUSION Although the study was limited by a cross-sectional design without direct control comparison, the findings suggest that patients with various psychiatric conditions treated with polypharmacy that includes VPA may have lower plasma carnitine levels than would be expected in healthy controls.
Collapse
Affiliation(s)
- Francisco A Moreno
- Department of Psychiatry, College of Medicine, University of Arizona Health Science Center, 1501 N. Campbell Avenue, 7-OPC, Tucson, AZ 85724, USA.
| | | | | |
Collapse
|
23
|
Carpenter LL, Moreno FA, Kling MA, Anderson GM, Regenold WT, Labiner DM, Price LH. Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. Biol Psychiatry 2004; 56:418-26. [PMID: 15364040 DOI: 10.1016/j.biopsych.2004.06.025] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2003] [Revised: 04/27/2004] [Accepted: 06/22/2004] [Indexed: 11/19/2022]
Abstract
BACKGROUND Vagus nerve stimulation (VNS) has shown promising antidepressant effects in treatment-resistant depression, but the mechanisms of action are not known. Cerebrospinal fluid (CSF) studies in epilepsy patients show that VNS alters concentrations of monamines and gamma-aminobutyric acid (GABA), neurotransmitter systems possibly involved in the pathogenesis of depression. METHODS Twenty-one adults with treatment-resistant, recurrent, or chronic major depression underwent standardized lumbar puncture for collection of 12 mL CSF on three separate but identical procedure days during participation in the VNS D-02 clinical trial. All subjects remained on stable regimens of mood medications. Collections were made at baseline (2 weeks after surgical implantation but before device activation), week 12 (end of the acute-phase study), and week 24. Cerebrospinal fluid concentrations of norepinephrine (NE), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) were determined with high-performance liquid chromatography. Concentrations of GABA were assayed with mass spectrometry. RESULTS Comparison of sham versus active VNS revealed a significant (mean 21%) VNS-associated increase in CSF HVA. Mean CSF concentrations of NE, 5-HIAA, MHPG, and GABA did not change significantly. Higher baseline HVA/5-HIAA ratio predicted worse clinical outcome. CONCLUSIONS Although several of the CSF neurochemical effects we observed in this VNS study were similar to those described in the literature for antidepressants and electroconvulsive therapy, the results do not suggest a putative antidepressant mechanism of action for VNS.
Collapse
Affiliation(s)
- Linda L Carpenter
- Laboratory for Clinical Neuroscience, Butler Hospital, Department of Psychiatry and Human Behavior, Brown University School of Medicine, Providence, Rhode Island 02906, USA. Linda_Carpenter_MD@Brown .edu
| | | | | | | | | | | | | |
Collapse
|
24
|
Opbroek A, Delgado PL, Laukes C, McGahuey C, Katsanis J, Moreno FA, Manber R. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 2002; 5:147-51. [PMID: 12135539 DOI: 10.1017/s1461145702002870] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Revised: 12/04/2001] [Indexed: 11/06/2022] Open
Abstract
Anecdotal and published case reports suggest that some patients taking selective serotonin reuptake inhibitors (SSRI) experience diminution in emotional responsiveness. This study aims to define the individual components of emotion disturbed in these patients. Fifteen patients reporting SSRI-induced sexual dysfunction completed the Laukes Emotional Intensity Scale (LEIS), a questionnaire about various emotions. Compared to controls, patients reported significantly (p<0.05) less ability to cry, irritation, care about others' feelings, sadness, erotic dreaming, creativity, surprise, anger, expression of their feelings, worry over things or situations, sexual pleasure, and interest in sex. Total score on the LEIS did not correlate with total score on the Hamilton Depression Rating Scale. In our sample, 80% of patients with SSRI-induced sexual dysfunction also describe clinically significant blunting of several emotions. Emotional blunting may be an under-appreciated side-effect of SSRIs that may contribute to treatment non-compliance and/or reduced quality of life.
Collapse
Affiliation(s)
- Adam Opbroek
- Department of Psychiatry, University of Arizona Health Sciences Center, USA
| | | | | | | | | | | | | |
Collapse
|
25
|
Moreno FA, Rowe DC, Kaiser B, Chase D, Michaels T, Gelernter J, Delgado PL. Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion. Mol Psychiatry 2002; 7:213-6. [PMID: 11840315 DOI: 10.1038/sj.mp.4000962] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2000] [Accepted: 06/15/2001] [Indexed: 11/09/2022]
Abstract
This study investigated the relationship between depressive symptom response during tryptophan (TRP) depletion and a functional polymorphism of the promoter region of the serotonin (5-HT) transporter gene (SLC6A4).(1) Forty-three subjects in remission from a major depressive episode who underwent TRP depletion were genotyped. DNA was extracted from blood lymphocytes or from cheek cells.(2) The two common alleles are designated long (l) and short (s). Depressive symptoms were measured with the 25-item Hamilton Depression Rating Scale (HDRS).(3) There was a significant association between the l homozygous genotype and the depressive response to TRP depletion, with a significant main effect of time (F = 8.763, df = 3, 38, P = <0.001), and time x l homozygous allele interaction (F = 3.676, df = 3, 38, P = 0.02). Individuals whose genotype predicted increased 5-HT transporter activity may be more susceptible to depressive changes in response to transient 5-HT perturbations. The use of endophenotypic markers for affective disorders such as the mood response to TRP depletion may facilitate studies of complex genetic traits such as depression by decreasing its heterogeneity.
Collapse
Affiliation(s)
- F A Moreno
- Department of Psychiatry, College of Medicine, The University of Arizona Health Sciences Center, Tucson, AR 85724, USA.
| | | | | | | | | | | | | |
Collapse
|
26
|
Delgado PL, Moreno FA, Onate L, Gelenberg AJ. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol 2002; 5:63-6. [PMID: 12057033 DOI: 10.1017/s1461145702002778] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Revised: 09/05/2001] [Indexed: 11/06/2022] Open
Abstract
This study was aimed at determining whether patient- or antidepressant-related variables are most important to the mood response to serotonin (5-HT) or catecholamine depletion. Depressed patients treated with open-label mirtazapine (>or=6 wk) received two depletion tests (5-HT and catecholamine depletion) 1 wk apart. Both 5-HT and catecholamine depletion led to a partial return of depression in most patients. Antidepressant response to mirtazapine is dependent on its dual actions on norepinephrine and 5-HT neurotransmission. Mood response to tryptophan or catecholamine depletion is dependent on the pharmacological properties of the antidepressant being taken during depletion.
Collapse
Affiliation(s)
- Pedro L Delgado
- Department of Psychiatry, Case Western Researve University School of Medicine, Cleveland, OH 44106-5080, USA.
| | | | | | | |
Collapse
|
27
|
Moreno FA, McGavin C, Malan TP, Gelenberg AJ, Heninger GR, Mathé AA, Delgado PL. Tryptophan depletion selectively reduces CSF 5-HT metabolites in healthy young men: results from single lumbar puncture sampling technique. Int J Neuropsychopharmacol 2000; 3:277-283. [PMID: 11343605 DOI: 10.1017/s1461145700002133] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2000] [Revised: 08/14/2000] [Indexed: 11/07/2022] Open
Abstract
Plasma tryptophan (Trp) depletion is a commonly used tool for determining the role of brain serotonin (5-HT) function in a variety of psychiatric disorders. This study measured the cerebrospinal fluid (CSF) monoamine metabolite response to Trp depletion and control testing in five healthy subjects utilizing a single lumbar puncture. Testing was done in a placebo-controlled, double-blind, randomized, cross-over design. Plasma-free and total Trp levels and behavioural ratings were obtained prior to and 5 h after ingestion of each amino-acid drink. CSF was obtained by performing a standard lumbar puncture 7 h after ingestion of the drink. Compared to control testing, Trp depletion caused a significant decrease of CSF 5-hydroxyindoleacetic acid (5-HIAA) (p = 0.03), but not of homovanillic acid or 3-methoxy-4-hydroxy-phenylglycol. Behavioural ratings were minimally affected in all subjects. This confirms that plasma Trp depletion reduces central nervous system measures of 5-HT function and suggests that the single lumbar puncture technique may be sufficient to detect the extent of CSF 5-HIAA changes during Trp depletion studies.
Collapse
|
28
|
Moreno FA, Delgado PL. Living with anxiety disorders: as good as it gets...? Bull Menninger Clin 2000; 64:A4-21. [PMID: 11002527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
The high prevalence of anxiety disorders, along with the high rate of associated comorbidity, leads to significant financial burden and human suffering, making early detection and proper intervention a clinical priority for these conditions. Despite advances in the understanding and treatment of anxiety disorders, a number of factors diminish the likelihood that people with anxiety will benefit from these advances. The authors discuss current issues relating to the treatment of anxiety disorders. This review highlights the need for recognition of comorbid conditions, the importance of reducing the high rates of partial treatment response, the importance of being aware of the common utilization of alternative treatment interventions, and the need to recognize and treat medication-induced sexual dysfunction.
Collapse
Affiliation(s)
- F A Moreno
- University of Arizona, College of Medicine, Tucson 85724, USA
| | | |
Collapse
|
29
|
Moreno FA, Heninger GR, McGahuey CA, Delgado PL. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry 2000; 48:327-9. [PMID: 10960166 DOI: 10.1016/s0006-3223(00)00893-3] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND This study investigated the relationship between depressive symptom response during tryptophan depletion and future depressive episodes. METHODS Twelve subjects with prior major depressive episodes in remission and medication-free for > or =3 months (patients), and 12 matched healthy (control) subjects received two tryptophan depletion tests 1 week apart. During follow-up the Hamilton Depression Rating Scale was administered weekly for 1 month, monthly for 3 months, and once at 6 and 12 months. RESULTS With results from both tests, tryptophan depletion has a sensitivity of 78%, specificity of 80%, positive predictive value of 70%, and negative predictive value of 86% to identify future depressive episodes. Survival analysis shows that mood response to tryptophan depletion reliably predicts major depressive episodes during the follow-up year (r =.2725, p =.014). CONCLUSIONS Tryptophan depletion may be clinically useful in identifying individuals at risk for future major depressive episodes.
Collapse
Affiliation(s)
- F A Moreno
- Department of Psychiatry, College of Medicine, The University of Arizona Health Sciences Center, Tucson 85724, USA
| | | | | | | |
Collapse
|
30
|
Delgado PL, Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry 2000; 61 Suppl 1:5-12. [PMID: 10703757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
This article reviews the role of norepinephrine (NE) and serotonin (5-HT) in depression and the therapeutic effects of antidepressant drugs from the perspective of human neurotransmitter depletion studies. The data reviewed suggest that both noradrenergic and serotonergic systems are involved in antidepressant action, but the specific impairment that underlies depression is unclear and is likely to vary among patients. Results from neurotransmitter depletion studies in depressed patients who have responded to treatment suggest that, while interactions between NE and 5-HT are likely, neither of these 2 neurotransmitter systems is the final common pathway for the therapeutic effect of antidepressant drugs. NE-selective antidepressant drugs appear to be primarily dependent on the availability of NE for their effects. Likewise, 5-HT-selective antidepressants appear to be primarily dependent on the availability of 5-HT for their effects. Antidepressants that cause effects on both noradrenergic and serotonergic systems-such as mirtazapine-may be dependent on the availability of both neurotransmitters for their effects. Neither 5-HT nor NE depletion induced clinical depression in healthy subjects or worsened depression in unmedicated symptomatic patients with major depression. This finding suggests that the cause of depression is more complex than just an alteration in the levels of 5-HT and/or NE. For some patients, depression may be more directly caused by dysfunction in brain areas or neuronal systems modulated by monoamine systems. We propose that antidepressant drugs may enhance neurotransmission in normal noradrenergic or serotonergic neurons and, through a time-dependent but as yet undiscovered process, restore function to brain areas modulated by monoamine neurons. Future research should focus on understanding the adaptive changes that follow enhancement of synaptic levels of monoamines in neuronal circuits of the frontal cortex, amygdala, and hippocampus. Research investigating the neurobiology of depression may be more informed if the focus is shifted to investigating areas of the brain modulated by monoamine systems rather than the monoamine systems themselves.
Collapse
Affiliation(s)
- P L Delgado
- Department of Psychiatry, University of Arizona Medical Center, Tucson, USA.
| | | |
Collapse
|
31
|
McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26:25-40. [PMID: 10693114 DOI: 10.1080/009262300278623] [Citation(s) in RCA: 634] [Impact Index Per Article: 26.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Although sexual dysfunction is common in psychiatric patients, quantification of sexual dysfunction is limited by the paucity of validated, user-friendly scales. In order to address this problem, the authors have developed the Arizona Sexual Experiences Scale (ASEX), a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction. This study assesses the internal consistency, test-retest reliability, and convergent and discriminant validity of the ASEX.
Collapse
Affiliation(s)
- C A McGahuey
- Department of Psychiatry, College of Medicine, University of Arizona, Tucson 85724, USA.
| | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
BACKGROUND Rapid and transient depletion of tryptophan (TRP) causes a brief depressive relapse in most patients successfully treated with and taking selective serotonin reuptake inhibitors, but little change in drug-free, symptomatic depressed patients. This study investigates the effects of TRP depletion in drug-free subjects in clinical remission from a prior major depressive episode (MDE). METHODS Twelve subjects with a prior MDE, currently in clinical remission and drug-free for at least 3 months (patients), and 12 healthy subjects without personal or family history of Axis I disorder (controls), received TRP depletion. The study was conducted in a double-blind, controlled [full (102-g) and quarter-strength (25 g) 15-amino acid drinks], crossover fashion. Behavioral ratings and plasma TRP levels were obtained prior to, during, and after testing. RESULTS All subjects experienced significant depletion of plasma TRP on both test-drinks, showing a significant dose-response relation. Healthy control subjects had minimal mood changes, but patients had a depressive response of greater magnitude. CONCLUSIONS In the context of prior TRP depletion studies with antidepressant-treated, and drug-free symptomatic depressed patients, these results suggest that depression may be caused not by an abnormality of 5-HT function, but by dysfunction of other systems or brain regions modulated by 5-HT.
Collapse
Affiliation(s)
- F A Moreno
- Department of Psychiatry, College of Medicine, University of Arizona Health Science Center, Tucson 85724, USA
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, Heninger GR, Charney DS. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999; 46:212-20. [PMID: 10418696 DOI: 10.1016/s0006-3223(99)00014-1] [Citation(s) in RCA: 198] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Brain serotonin (5-HT) content is dependent on plasma levels of the essential amino acid, tryptophan (TRP). We have previously reported that rapid TRP depletion more frequently reversed the antidepressant response to monoamine oxidase inhibitors and 5-HT reuptake inhibitors than to desipramine (DMI). This study further investigates the relationship of relapse during TRP depletion to antidepressant type in nonrefractory, depressed patients randomly assigned to treatment with either DMI or fluoxetine (FLU). METHODS Fifty-five drug-free depressed (DSM-III-R) patients were randomly assigned to antidepressant treatment with either DMI or FLU. All patients were either treatment naive (n = 34) or had previously received successful antidepressant treatment (n = 21). During the treatment phase, 35 patients had therapeutic responses by predetermined criteria (DMI 18/25; FLU 17/23) and 30 of these (15 DMI responders and 15 FLU responders) went on to TRP depletion testing. Patients received two 2-day test sessions involving administration of similar amino acid drinks. One session led to rapid TRP depletion and the other did not. Behavioral ratings [Hamilton Depression Scale (HDRS)] and plasma for TRP levels were obtained prior to, during, and after testing. Relapse was defined as a 50% increase in HDRS with total < or = 17. RESULTS Total and free TRP decreased 70% to 80% 5 hours after the TRP-free drink. While 8/15 FLU responders relapsed, only 1/15 of the DMI responders relapsed. No patient experienced significant depressive symptoms during control testing. CONCLUSIONS Rapid depletion of plasma TRP transiently reverses the antidepressant response in many patients on FLU but not DMI. Depressive relapse during TRP depletion appears to be more related to antidepressant type than to patient variables since patients were randomly assigned to the two treatments. Antidepressant response to FLU appears to be more dependent on 5-HT availability than that of DMI, suggesting that antidepressants mediate their therapeutic effects through different mechanisms.
Collapse
Affiliation(s)
- P L Delgado
- Department of Psychiatry, West Haven Department of Veterans Affairs Medical Center, Yale University School of Medicine, New Haven, CT, USA
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Delgado PL, Moreno FA. Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder. Br J Psychiatry Suppl 1998:21-5. [PMID: 9829023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
BACKGROUND There is a major role for serotonin in the mechanism of anti-obsessional drug action. Drugs that block uptake of noradrenaline are not effective in the treatment of obsessive-compulsive disorder (OCD), while drugs that potently bock serotonin reuptake are effective. While enhancement of serotonin neurotransmission is clearly involved in the treatment of OCD, the role of serotonin in the pathophysiology of OCD is less clear. METHOD This paper provides a brief, focused review of the literature regarding treatment of OCD, the effects of drugs with selective action at various serotonin receptors and results of neurotransmitter depletion studies in patients with OCD. RESULTS Some patients with OCD may experience remission of OCD symptoms during intoxication with psychedelic drugs that have potent 5-HT2A/2C agonist activity. These findings, coupled with results from serotonin depletion studies in depressed and OCD patients, suggest that enhancement of serotonin neurotransmission may underlie both antidepressant and anti-obsessional drug action, although the targeted brain areas may differ. CONCLUSIONS OCD may not involve a dysfunction of the serotonin system. Rather, it is more likely to involve a dysfunction of specific brain circuits, particularly in the frontal cortex. Modulation of these circuits by serotonin neurons may underlie the specific action of anti-obsessional drugs.
Collapse
Affiliation(s)
- P L Delgado
- Department of Psychiatry, University of Arizona College of Medicine, Tucson 85274, USA
| | | |
Collapse
|
35
|
Abstract
The serotonin (5-HT) neurotransmitter system has been implicated in the pathophysiology of several neuropsychiatric disorders, especially obsessive-compulsive disorder (OCD). Blockade of 5-HT reuptake appears to be an important initial neurobiological event in the therapeutic mechanism of action of antiobsessional drugs. However, for reasons that continue to be poorly understood, clinical improvement following initiation of treatment with 5-HT reuptake inhibitors can take up to eight to 12 weeks, and most patients do not fully improve. Recent data suggest that activation of 5-HT2A and/or 5-HT2C receptors may be important for the improvement of OCD symptoms. Most psychedelic drugs are potent agonists at 5-HT2A and 5-HT2C receptors and their binding potency to these receptors is strongly correlated with their human potency as hallucinogens. This article will briefly review the relevant clinical and preclinical studies relating to the effects of hallucinogens on OCD. These data suggest that activation of 5-HT2 receptors by hallucinogens may lead to acute reduction of, as well as possible longer-lasting beneficial effects on, the symptoms of OCD. Evidence for and against involvement of 5-HT2A and/or 5-HT2C receptors in the therapeutic effects of drug therapies for OCD are reviewed. Issues related to the pharmacological properties and safety of psychedelic drugs, when considered as potential treatments for patients with OCD, are summarized. The authors suggest that controlled trials of potent 5-HT2 agonists in people suffering from OCD are warranted.
Collapse
Affiliation(s)
- P L Delgado
- University of Arizona College of Medicine, Tucson 85724, USA.
| | | |
Collapse
|
36
|
Abstract
BACKGROUND Recent uncontrolled reports describe a dramatic and rapid improvement of depressive symptoms in patients treated with the combination of pindolol and serotonin selective reuptake inhibitors or monoamine oxidase inhibitors. The present study attempts to replicate those findings. METHOD Ten outpatients with current DSM-III-R major depressive disorder who had failed to obtain or maintain an appropriate response to an adequate trial of antidepressant drug were included in a randomized double-blind, placebo-controlled, crossover study. Subjects received pindolol 2.5 mg p.o. t.i.d. or placebo for 2 weeks in addition to their current antidepressant. Clinical monitoring, vital signs, and behavioral ratings were performed weekly for the duration of the study. RESULTS Pindolol was well tolerated by all patients. None of the subjects experienced significant symptom worsening during the addition of either placebo or active drug. At the end of the 2-week trial, there was no statistically significant difference between pindolol augmentation and placebo. Two patients had a categorical response during placebo treatment. No categorical responses were observed during pindolol augmentation. CONCLUSION This study failed to replicate the rapid and dramatic response to pindolol augmentation in treatment-resistant depressed patients.
Collapse
Affiliation(s)
- F A Moreno
- Department of Psychiatry, University of Arizona Health Sciences Center, Tucson 85724, USA
| | | | | | | |
Collapse
|
37
|
|
38
|
Pinilla LC, Vásquez E, Moreno FA, Talavera D, Mendoza N, Donderis C, Toro J. [Identification of coagulase-negative staphylococci in hospitalized patients]. Rev Med Panama 1985; 10:111-5. [PMID: 4023296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|